Early Detection, Active Surveillance and Improved Outcomes for Prostate Cancer.
Holland Hospital and Western Michigan Urological Associates are the first in the region to offer UroNav Fusion Biopsy, an innovative new technology for more precise and accurate detection of prostate cancer.
Prostate cancer is the most common cancer in men, affecting 1 in 7, and is the second leading cause of death in men. There are two categories of men who are likely to derive the greatest benefit from UroNav. First are those who’ve had one or more negative prostate biopsies in the past where there is continued concern of prostate cancer. The second are men who choose active surveillance as a management strategy.
UroNav advances the “active surveillance” approach of suspicious lesions in the prostate. The MRI of the prostate is performed at the hospital. The urologist fuses MRI images with ultrasound images during the biopsy to provide real-time visualization of the suspected lesions. This GPS-like tracking identifies suspicious areas that can be targeted during office-based prostate biopsy, which may improve the accuracy and precision of those biopsies.
“The option of active surveillance for prostate cancer has been increasingly popular as we realize that some cancers can be watched prior to pursuit of treatment,” says Adam Kadlec, MD, “UroNav helps patients on active surveillance identify whether they’d benefit from further cancer treatments. Or, it may reassure them that they can continue to be watched safely.”
UroNav is a cutting-edge diagnostic tool that may become a new standard of care for early detection and active surveillance of prostate cancer.
UroNav Fusion Biopsy